Evaluation of the safety issues of antiplatelet agents in acute-phase treatment and secondary prevention of cerebral thrombosis in patients with history of cerebral hemorrhage
10.3760/cma.j.issn.0254-9026.2010.09.005
- VernacularTitle:抗血小板治疗对伴脑出血史的脑梗死患者急性期及二级预防的安全性评价
- Author:
Zhimin WANG
;
Lei WANG
- Publication Type:Journal Article
- Keywords:
Cerebral hemorrhage;
Cerebral thrombosis;
Risk assessment
- From:
Chinese Journal of Geriatrics
2010;29(9):718-720
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the safety issues of antiplatelet agents in the acute-phase treatment and secondary prevention of cerebral thrombosis in patients with history of cerebral hemorrhage. Methods The 149 cerebral thrombosis patients with history of cerebral hemorrhage were assigned to the test group, while the 405 cerebral thrombosis patients without history of hemorrhage stroke were assigned to the control group. The patients in the two groups were continuously treated with antiplatelet agents during hospitalization and after discharge. Cumulative incidences of cerebral hemorrhage were observed during hospitalization and 1.5 years after discharge.Results During hospitalization, 7 patients in the test group and 16 patients in the control group were noted with cerebral hemorrhage attack (no death were recorded because of cerebral hemorrhage).And at 1.5 years after discharge, 15 patients in the test group and 36 patients in the control group were noted with cerebral hemorrhage attack (no death were recorded because of cerebral hemorrhage).Conclusions There are no increased cerebral hemorrhage risks for patients who have a history of cerebral hemorrhage to take antiplatelet agents during the acute phase and secondary prevention of cerebral thrombosis.
